Alto Neuroscience Files 8-K
Ticker: ANRO · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Alto Neuroscience filed an 8-K on 5/31, reporting material agreements and equity sales.
AI Summary
On May 31, 2025, Alto Neuroscience, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing was made on June 3, 2025.
Why It Matters
This 8-K filing indicates significant corporate actions by Alto Neuroscience, Inc., including definitive agreements and equity sales, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 001-41944 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-4210124 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Registrant
- May 31, 2025 (date) — Date of earliest event reported
- June 3, 2025 (date) — Filing date
- 001-41944 (company) — SEC File Number
- 83-4210124 (company) — IRS Employer Identification No.
FAQ
What type of material definitive agreement did Alto Neuroscience, Inc. enter into?
The filing states that Alto Neuroscience, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 31, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on June 3, 2025.
What are the principal executive offices of Alto Neuroscience, Inc.?
The principal executive offices are located at 650 Castro St, Suite 450, Mountain View, CA 94041.
Besides the material definitive agreement, what other significant events are reported?
The filing also reports on unregistered sales of equity securities and other events.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Alto Neuroscience, Inc. (ANRO).